Brian Wilson: Customizing cancer treatment with nanoparticles

A new approach to cancers of the lung and esophagus shows promise for less invasive, more targeted treatment.

29 October 2014

Brian C. Wilson is Professor of Medical Biophysics and Head of the Division of Biophysics and Bioimaging at the Ontario Cancer Institute/University of Toronto since 1993.

A graduate in Natural Sciences from Glasgow University, Scotland, he worked at the Institute of Cancer Research/Royal Marsden Hospital in London and then in Australia before moving to McMaster University/Hamilton Cancer Center, Canada in 1981, where he initiated a research program in photodynamic therapy (PDT). This developed into a broad program in biophotonics, including fundamental studies in optical biophysics and translational/clinical projects in early cancer detection, PDT for brain, GI and prostate cancer, fluorescence image-guided surgery, and new technologies for molecular pathology. Recently, this program has expanded to the use of nanoparticles as image contrast agents for endoscopy and molecular pathology.

Wilson has published over 400 scientific papers. He has held Visiting Professor positions at Harvard University/MGH and University of Sao Paulo, Brazil and is currently Professor-at-Large, Institute of Advanced Studies, University of Western Australia.

He serves on numerous national and international research advisory committees, is a consultant to several Canadian, European and US biophotonics companies and is co-founder of three bioimaging/therapeutics companies.

Recent News
PREMIUM CONTENT
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?
close_icon_gray